Evidence mapPaperPMID 41596311Full record

ArticleInternational journal of molecular sciences2026

SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights.

Eleonora Saraceno, Ilaria Serra, Beatrice Bracci, Veronica Pagliardini, Michele Pinon, Gerdi Tuli, Antonia Versace, Claudia Bondone, Marco Spada

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eleonora SaracenoDepartment of Public Health and Pediatrics, Postgraduate School of Pediatrics, Regina Margherita Children's Hospital, University of Torino, 10126 Torino, Italy.ORCID 0009-0006-8103-5417
Ilaria SerraDepartment of Public Health and Pediatrics, Postgraduate School of Pediatrics, Regina Margherita Children's Hospital, University of Torino, 10126 Torino, Italy.
Beatrice BracciDepartment of Public Health and Pediatrics, Postgraduate School of Pediatrics, Regina Margherita Children's Hospital, University of Torino, 10126 Torino, Italy.ORCID 0009-0001-7519-9849
Veronica PagliardiniDepartment of Pediatrics, Regina Margherita Children's Hospital, University of Torino, 10126 Torino, Italy.
Michele PinonPediatric Gastroenterology Unit, Regina Margherita Children's Hospital, 10126 Torino, Italy.
Gerdi TuliPediatric Endocrinology Unit, Regina Margherita Children's Hospital, 10126 Torino, Italy.ORCID 0000-0001-5862-8958
Antonia VersacePediatric Emergency Department, Regina Margherita Children's Hospital, 10126 Torino, Italy.
Claudia BondonePediatric Emergency Department, Regina Margherita Children's Hospital, 10126 Torino, Italy.
Marco SpadaDepartment of Pediatrics, Regina Margherita Children's Hospital, University of Torino, 10126 Torino, Italy.ORCID 0000-0002-8894-350X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disorder caused by fumarylacetoacetate hydrolase deficiency, leading to the accumulation of toxic metabolites such as fumarylacetoacetate (FAA) and succinylacetone (SA). We report an 11-year-old boy with poorly controlled HT1 who presented with a severe neurovisceral crisis after suboptimal adherence to nitisinone (NTBC) therapy, characterized by abdominal pain, hypertension, paralytic ileus, seizures, and profound hyponatremia. Biochemical evaluation revealed markedly elevated urinary δ-aminolevulinic acid (ALA), consistent with a porphyria-like metabolic decompensation, together with inappropriately increased plasma copeptin in the setting of hypotonic hyponatremia and clinical euvolemia, fulfilling diagnostic criteria for the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Optimization of NTBC therapy combined with tailored fluid management resulted in complete clinical and biochemical recovery. This case supports a pathophysiological link between acute disruption of the heme-porphyrin pathway and inappropriate antidiuretic hormone secretion. In HT1, this susceptibility may be further amplified by FAA- and SA-mediated oxidative stress, mitochondrial dysfunction, and heme depletion, with an additional contribution from SA-associated renal tubular impairment. Overall, our findings underscore SIADH as a potentially underrecognized cause of acute hyponatremia in HT1 and highlight the importance of strict NTBC adherence and early monitoring of urinary ALA during metabolic decompensation.

Indexed as

Inappropriate ADH SyndromePorphyriasTyrosinemiasChildCyclohexanonesHeptanoatesHumansHyponatremiaMaleNitrobenzoatesCyclohexanonesHeptanoatesnitisinoneNitrobenzoatessuccinylacetoneacute porphyriahereditary tyrosinemia type 1hyponatremianitisinoneSIADH

Identifiers

PMID41596311
PMCPMC12841044

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.